InMed Pharmaceuticals Inc. — Director's Dealing 2020

Nov 12, 2020

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: InMed Pharmaceuticals Inc. (INM)
CIK: 0001728328
Period of Report: 2020-11-12

Reporting Person: Sazdanoff Catherine (Director)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Director Stock Option (Right to Buy)	$6.33	2025-01-11	Common Shares (1061)		Direct
Director Stock Option (Right to Buy)	$8.35	2024-07-01	Common Shares (3030)		Direct

Footnotes

F1: Converted from Canadian exercise price of C$8.25 using an exchange rate of C$1.3039 = US$1.00.

F2: Converted from Canadian exercise price of C$10.89 using an exchange rate of C$1.3039 = US$1.00.

F3: 1,344 of the options have vested. The remaining 1,686 options will vest monthly through July 1, 2022.

F4: The options were granted on January 12, 2020, and will fully vest on the earlier of January 12, 2021, or immediately prior to the Issuer's next annual general meeting.